The Shot That Wears Off Too Fast
When you think about mRNA technology — the kind used in COVID-19 vaccines — you might think of a single-strand message that the body reads and then discards quickly. That's by design for some uses. But for treating cancer or a rare genetic disease, doctors often want that message to last longer.
What if the molecule never had an end? What if it formed a ring?
Why RNA Shape Changes Everything
RNA (ribonucleic acid) is the molecule that carries genetic instructions inside your cells. Standard mRNA is a linear strand — it has a beginning and an end. Enzymes in your body quickly find those ends and begin breaking the molecule down. That's efficient for a vaccine, but limiting for a longer-term treatment.
Circular RNA (circRNA) is structurally different: it's a closed loop with no loose ends. In theory, this makes it far harder for the body's enzymes to degrade — similar to the difference between a rope with frayed ends (easy to unravel) and a closed loop (no starting point to attack).
This is not a new discovery in nature. Human cells already produce their own circular RNAs for various regulatory purposes. But scientists are now engineering synthetic circular RNAs — designed from scratch in a lab — to carry specific therapeutic instructions.
Old Meds vs. the Ring Approach
Standard mRNA medicines last hours to a few days inside cells before being broken down. That works for triggering an immune response (as in a vaccine), but it limits the use of mRNA for chronic diseases that require sustained protein production.
Circular RNA, in some laboratory studies, has shown the ability to persist significantly longer — in some cases producing proteins for weeks rather than days. This opens up potential uses that linear mRNA simply can't match: a single dose that keeps working for an extended period, or a cancer therapy that trains immune cells over a longer window.
But here's the catch: performance varies enormously depending on how the circle is made.
How Scientists Build These Rings
Creating a functional circular RNA is more complex than it sounds. The molecule has to be circularized (its ends joined together) using specific chemistry. Different joining methods leave different "fingerprints" on the molecule, affecting how well it works and how the immune system reacts to it.
A new review in Frontiers in Medicine, covering studies published between 2018 and late 2025, explains that impurities created during the circularization process — including fragments of linear RNA and double-stranded RNA (RNA in which two strands are twisted together rather than one) — can trigger strong immune reactions that undermine the therapy's effectiveness.
Think of it like baking bread: if your yeast is contaminated, the whole loaf is affected. Purifying circular RNA to remove these byproducts is one of the field's biggest current challenges.
This doesn't mean circular RNA drugs are coming to pharmacies soon — the field is promising but still working through fundamental manufacturing problems.
The researchers surveyed preclinical studies (laboratory and animal studies done before human testing) across three major disease areas: oncology (cancer), immunology (immune system conditions, including vaccine strategies), and rare or chronic diseases.
In cancer research, circRNA showed promise as a way to produce tumor-fighting proteins or to "program" immune cells to attack cancer for extended periods. In vaccine research, early results suggested circRNA could sustain antigen (the protein that triggers immunity) production longer than standard mRNA — potentially allowing fewer doses.
For rare genetic diseases where a protein is missing or dysfunctional, circRNA could in theory serve as a long-acting replacement — one dose providing therapeutic protein production for weeks.
The Critical Questions Still Unanswered
The review is careful to distinguish what is genuinely promising from what is still speculation. One important point: claims that circular RNA is automatically "less immunogenic" (less likely to cause an immune reaction) than standard mRNA are not reliably true. It depends heavily on how the circRNA was made, how pure it is, and how it's delivered into cells.
The authors propose a three-axis framework for thinking about when circRNA might actually be better than existing options — suggesting it has clear advantages in specific situations (like a single-dose local treatment or extended antigen production) but may not outperform optimized mRNA in many standard scenarios.
What Experts in the Field See
Researchers are now calling for standardized purity testing, direct head-to-head comparisons with mRNA, and deeper investigation into how the immune system responds to different types of circular RNA. Without these benchmarks, it's difficult to know when to choose circRNA over already-approved alternatives.
Computational models (computer simulations that predict how molecules will behave) are also being developed to accelerate which circular RNA sequences and structures are most likely to work in specific diseases.
If you or a loved one is living with cancer, a rare genetic disease, or a chronic immune condition, circular RNA represents a genuinely interesting direction for medicine — but it is not yet an available treatment. No circular RNA drug has been approved by the FDA or EMA (European Medicines Agency) as of this writing.
If you're interested in clinical trials involving novel RNA therapies, clinicaltrials.gov is the best place to search for open studies in your condition. Talk to your specialist before making any decisions about experimental treatments.
The Limits of This Research
This review focused on preclinical and early translational research — mostly laboratory studies, with some early human data. The field lacks large, randomized human trials. Manufacturing standards are not yet unified across research groups, which makes comparing results between studies difficult.
The next key steps are establishing standardized manufacturing and purity protocols, launching head-to-head trials comparing circular RNA to optimized mRNA, and identifying specific diseases where the long-acting nature of circRNA provides a clear clinical advantage. Early-phase human trials in oncology and rare diseases are beginning to emerge. The technology is real — but proving it works better than existing options will take years of careful clinical testing.